Schizotypal Personality Test.

Post Reply New Topic

:lol: I don't know. are people still using psychedelic drugs? much? i thought they were a thing of another era. i could be wrong

...low dose of LSD.

I think they're doing trials with low doses of LSD for OCD. FYI and all that....

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

This study is currently recruiting patients.
Verified by Heffter Research Institute December 2005Sponsored by: Heffter Research Institute
Information provided by: Heffter Research Institute
ClinicalTrials.gov Identifier: NCT00302744



Purpose

PSYCHIATRIC RESEARCH STUDY FOR CANCER PATIENTS

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain. Condition Intervention Phase
Anxiety Drug: Psilocybin (drug) Phase I


MedlinePlus consumer health information

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Official Title: Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Further study details as provided by Heffter Research Institute:

Total Enrollment: 7

Study start: April 2004

The significance of this study is that it is addressing the important issues of psychological and spiritual well being of people who have advanced cancer. In 2001, the National Cancer Policy Board of the Institute of Medicine and National Research Council issued a report (Improving Palliative Care for Cancer: Summary and Recommendations) that specifically recommended research be conducted using novel agents and methods. Psilocybin is a novel agent which produces a profound alteration in your state of consciousness. It is the main active ingredient found in “magic mushrooms”.

Our specific aim is to learn whether this psychoactive drug, psilocybin, might be effective in reducing anxiety, depression and physical pain, and therefore improving your quality of life. This pilot study will start with 12 people ages 18-70. For each participant there will be two overnight admissions to the hospital. In one session you will be given a placebo and in the other you will get the active medication, but no one will know which drug is administered when. This is called a double blind study. You will be asked to fill out questionnaires about how you feel, your pain levels and your moods. There will also be at least two psychotherapy meetings before the study sessions, so that you are fully aware of what to expect and to have all your questions answered.

We cannot take you in the study if you have central nervous system (CNS) cancers, kidney disease, diabetes, abnormal liver function tests, epilepsy, cardiovascular disease including untreated high blood pressure (BP greater than 140/90), and pregnancy. The psychiatric exclusions are: you or an immediate family member with a history of a major psychiatric disorder, a current substance abuse problem, or an anxiety or a mood disorder within 1 year prior to the onset of symptoms of your current illness.

We also cannot take you in the study if you are taking certain medications, such as: anti-seizure, insulin and oral hypoglycemics, and cardiovascular drugs (except anti-hypertensive medications). Some antidepressant (SSRIs) medications cannot be taken within the two weeks prior to the session. (Except for Prozac, which cannot be taken in the last 5 weeks prior to the session.)

You will get a MRI of the brain prior to admission (if you haven’t had one in the prior two months), at the study’s expense, to be sure there is no CNS involvement. You can provide us, or the study will pay for, lab work from the prior 2 weeks (CBC, liver function and renal function). The history and physical, neurological exam, EKG, and a urine pregnancy test (if you are a woman with child-bearing potential), will be done on admission by the house staff doctors.

You will be allowed to take your own medications while in the hospital, and will be encouraged to bring to the hospital personal photos, small memorabilia, and some of your favorite music that can be played during the sessions.

Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria

Inclusion Criteria:
Have advanced-stage cancer and anxiety.
Be between the ages of 18 – 70.

Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times.

Exclusion Criteria:
Not have cancer that affects the central nervous system or brain function.
Have no history of major psychiatric disorder.
Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension.
Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs).
May take PRN benzodiazepines up to 3 days before the session.
No Prozac for the previous 5 weeks.
No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration.
No alcohol consumption the day before, the day of, and the day after a session.
Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.

Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00302744

Alicia Danforth, Coordinator 310-222-3175 adanforth@earthlink.net
Charles S. Grob, MD 310-222-3175 grob@humc.edu

United States, California
Harbor-UCLA Medical Center, Torrance, California, 90509, United States; Recruiting
Charles S. Grob, MD, Principal Investigator

Study chairs or principal investigators

Charles S. Grob, MD, Principal Investigator, University of California, Los Angeles

More Information
Study ID Numbers: HEFFTER11287-01
Last Updated: March 28, 2007
Record first received: March 10, 2006
ClinicalTrials.gov Identifier: NCT00302744
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on July 26, 2007

While the neurobiology of OCD and schizophrenia has been extensively studied in the past decade, there is lack of controlled study in patients with OC schizophrenia. The research evidence implicates dysfunction of dorsolateral prefrontal cortex circuit in schizophrenia and cortico-striatal-thalamic-cortex in OCD, and both disorders involve predominantly dopaminergic and serotonergic neurotransmitter systems.[17,18] A recent paper that examined the neuroanatomical abnormalities in OCD, schizotypal OCD, and schizophrenia showed a significant gray matter volume reduction suggested that that the schizotypal OCD may be a distinct neuropathological process.

I gladly yield the high score to you, sir. [If I've kept track of high scores properly.]

Though, in all honesty, I think RainSong could give us both a run for our money, and win.

The profound and terrifying ego-loss experience induced by 8 hits of lsd had unanticipated effects. Over the next several months, I became increasingly "religious", perfectly confident that my soul had literally touched the divine. Subsequent lower-dose experiments induced religious and mystical experiences that I would have thought inaccessable at all but the highest doses.

you can be diagnosed with this personality disorder alongside a pervasive development disorder

funny how that works eh?

[excuse me, you CANNOT be diagnosed....]

http://www.csp.org/nicholas/A5.html

Reading up on LSD and ego. Here is a quote from the above link of one guys self report.